Tag: jpmorganchase
Despite Pandemic Pressures, Big Banks Screwed Consumers On Overdrafts

Despite Pandemic Pressures, Big Banks Screwed Consumers On Overdrafts

Reprinted with permission from Daily Kos

Last year was a difficult one for millions of people in the United States.

It was not so difficult for big banks, and one of the ways the banks raked in revenue was by hitting struggling people with overdraft fees.

During the final quarter of 2020, when the coronavirus pandemic was battering the country, JPMorganChase, Bank of America, and Wells Fargo each took in more than $300 million in overdraft fees alone. Those fees are slapped on people who are by definition struggling, and banks often use strategies to maximize the number of fees people pay, like ordering transactions so that the biggest amounts go through first, which lets them charge fees on more, smaller transactions. And it's no thanks to the banks that it wasn't much, much worse—COVID-19 relief from the government protected many people from the worst.

Around one in three checking accounts has at least one overdraft a year, and five percent of checking account holders have 20 or more overdrafts a year, accounting for more than 60 percent of overdraft fees. In 2020, the average overdraft fee was over $33. Many of these fees are triggered by debit card transactions for less than $25 that are repaid within three days.

This is an ongoing story—bank overdraft fee policies have been terrible for years. But it took on new dimensions during the pandemic, with sky-high unemployment creating a financial emergency for so many people.

"Banks could've capped overdraft fees for a certain number of months, or had no fees during the pandemic, but they didn't want to give up a dollar of overdraft revenue in any formal way," Rebecca Borné, senior policy counsel at the Center for Responsible Lending, told The American Prospect's Alexander Sammon. "So what we see now is a return to business as usual, where our largest banks each took over a billion dollars out of the checking accounts of people during one of the worst years in our history. It's a gobsmacking amount of money."

It would have been much worse without COVID-19 relief bills, from the CARES Act to the American Rescue Plan. Check out how Google trend data on searches for "overdraft" tracked the passage of those laws:

OverdraftandGoogleSearches1.png

After each round of relief payments, you see searches for "overdraft" drop. Because the banks weren't interested in going easy on people being hammered by a once-in-a-century pandemic and the accompanying economic devastation.

Consider it one more reminder that what we need are regulations and laws to protect consumers. There are two prime ways that could happen on this issue. Early in the pandemic, Sens. Cory Booker (D-NJ) and Sherrod Brown (D-OH) proposed legislation to crack down on overdraft fees during the COVID-19 emergency, banning them altogether for the duration of the emergency and preventing banks from reporting overdrafts to credit reporting agencies—but that didn't get passed. Booker and Rep. Carolyn Maloney (D-NY) have other legislation on overdraft abuses more generally, but as always, there's that Senate filibuster problem blocking progress.

Under President Biden, though, the Consumer Financial Protection Bureau (CFPB) could do a lot more protecting consumers than the agency did under Donald Trump. Biden's nominee to head the CFPB, Rohit Chopra, hasn't yet been confirmed, but he's known as a strong consumer advocate. He could regulate the practice, which is extraordinarily abusive even in non-pandemic times.

Can These Corporate Titans Reform Health Care — And Tame Big Pharma?

Can These Corporate Titans Reform Health Care — And Tame Big Pharma?

President Trump offered few words about health care in his State of the Union address. He did mention drug prices, though.

“One of my greatest priorities is to reduce the price of prescription drugs,” he said. “In many other countries, these drugs cost far less than what we pay in the United States. … That is why I have directed my administration to make fixing the injustice of high drug prices one of my top priorities.”

Which is an interesting thing for Trump to say, given that he has just made Alex Azar, a top executive at drugmaker Eli Lilly, head of Health and Human Services. Lilly tripled the price of insulin during Azar’s tenure there. Suffice it to say, the one injustice Eli Lilly does not want to fix is high drug prices.

There was a bigger story going on, and it was not unrelated. Amazon, Berkshire Hathaway and JPMorgan Chase announced that they are putting their heads together to create a health care plan for their 1.1 million U.S. employees. Sounds like leverage to me. Eight states have fewer people.

During the presidential campaign, Trump vowed that if elected, he would have Medicare negotiate more favorable drug prices with the manufacturers. Since he took office, that pledge has not seen the light of day.

Washington was never good at standing up to the medical-industrial complex. There’s too much money to be made in standing down. And a separation between the public’s wallet and Big Pharma’s desire to extract huge profits is surely one wall Trump will never build.

But the medical industry does not own Amazon, the world’s largest internet company, or Berkshire Hathaway, the conglomerate Fortune ranks as America’s third-most profitable company, or JPMorgan Chase, America’s biggest bank.

The fine details have yet to be revealed, but the stated plan is to create a company that would be free from profit-making incentives. That’s not great news for profit-oriented suppliers. The stocks of UnitedHealth Group, Aetna and CVS — which plans to buy Aetna — all took a beating after the announcement.

The partners say they will use technology to simplify the delivery of health care. And they insist the new system will improve the services available to employees.

The beauty of this corporate trio’s gambit is they are bypassing the politicians. Their aim is to “disrupt” the forces that saddle them with exorbitant prices.

“The ballooning costs of health care act as a hungry tapeworm on the American economy,” Warren Buffett, Berkshire’s fabled CEO, stated with trademark simplicity.

Wonder what they’re going to do about drug prices. The drug Humira offers a window into the challenges.

According to the ads, Humira enables a woman hurting from rheumatoid arthritis to chase her puppy all over the house. (“Ask your doctor about Humira.”) In 2012, Humira cost a ridiculous $19,000 a year. Its maker, AbbVie, recently raised the price to a piratical $38,000.

The bottom line is that the U.S. spends nearly twice as much on health care as a percentage of the economy as do other industrialized countries — while its people use about the same amount of health care. Corporate America has long objected to what this costly health care is doing to its bottom line.

So bringing down the prices is the big game in taming total health care spending. No one says this will be easy, and doubters point to past failed corporate efforts. But these are three giants who don’t scare easily. Amazon has already shown interest in selling pharmaceuticals.

Since Washington won’t do much about the prices for health care, let’s see what Amazon, Berkshire and JPMorgan come up with. Go forth and disrupt, we say.

Follow Froma Harrop on Twitter @FromaHarrop. She can be reached at fharrop@gmail.com. To find out more about Froma Harrop and read features by other Creators writers and cartoonists, visit the Creators webpage at www.creators.com.

PHOTO: Warren Buffett, chairman and CEO of Berkshire Hathaway, speaks  in Washington, D.C.,  October 13, 2015. REUTERS/Kevin Lamarque